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a b s t r a c t
We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe
constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the
JAK2V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib. Within
4 weeks the patient achieved complete hematological remission with normalization of peripheral blood
counts and within 10 months the JAK2V617F-allele burden was reduced from 90% to 28%. Such a rapid
decline in the JAK2V617F allele burden is highly unusual in PV-patients during low-dose IFN-alpha2
monotherapy and this ﬁnding warrants a prospective study with combination therapy.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Case report
A 55-year old woman with PV diagnosed in the precursor stage of
ET 12 years ago was referred due to intolerance to hydroxyurea (HU)
(fever and exanthema) and pegylated interferon-alpha2b (PEG-Intron)
(exanthema). Since 2009 the patient had suffered two episodes of
transitory cerebral ischemia (TCI). Accordingly, permanent treatment
with clopidogrel had been instituted. Several CT-scans were normal.
At the time of referral, the patient received treatment with anagrelide
and clopidogrel. On admission, the patient's hemoglobin concentration
was 11.9 g/dL, the leukocyte count was 21.9109/L and the platelet
count was elevated at 526109/L. CRP and plasma lactate dehydro-
genase (LDH) levels were normal. A bone marrow biopsy was
compatible with a diagnosis of PV with grade 1 reticulin ﬁbrosis.
A peripheral blood-smear showed no leucoerythroblastosis. The
patient still needed phlebotomies to keep the hematocrit below
0.42, a total of four being performed within the last six months prior
to referral. An abdominal ultrasound revealed a spleen length of 20 cm
giving rise to intermittent spleen pain and abdominal discomfort.
Because of hypermetabolic symptoms, pronounced abdominal dis-
comfort, and intolerance of PEG-Intron and HU, treatment with Rux
was initiated at a dose of 20 mg twice daily and anagrelide was
discontinued. Within the ﬁrst 3 days of Rux therapy, the patient
experienced remarkable clinical improvement with resolution of
severe fatigue, night sweats, abdominal pain and pruritus, which
had negatively inﬂuenced the patient's quality of life during the past
2–3 years. Four days after starting Rux, the patient acutely experienced
TCI-like symptoms with transient decrease of strength in the left arm
and abnormal sensations in the left half of the tongue and neck. The
symptoms were very similar to those which the patient had experi-
enced during previous attacks of TCIs. The blood values disclosed a
slight decrease in the leukocyte count (17.6109/L) but an increase in
the platelet count (573109/L). A CT-scan was normal. Because the
platelets were elevated, Rux therapy was combined with PEG-IFN-
alpha2a (Pegasys) at a low dose of 45 mg every second week. After
1 month a complete hematologic remission (CHR) was achieved
(Fig. 1) and after 2.5 months an abdominal ultrasound revealed a
reduction in spleen length from 20 cm to 13.8 cm. After 6 months the
spleen was no longer palpable.
The combination therapy was exceedingly well tolerated with-
out any side effects to either drug. Remarkably, despite an
advanced PV-stage the JAK2V617F allele burden was rapidly
lowered from 90% mutated alleles at referral to 59% at 6 months,
28% at 10 months and 12% at 16 months of therapy (Fig. 2).
Furthermore, the patient had both her carotid arteries scanned
by ultrasound because of the TCI-symptoms, and the physician
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(not knowing that the patient had started therapy) described an
improvement of the blood-ﬂow (initially turbulent ﬂow, but
approximately one year later the ﬂow was more laminar).
2. Discussion
This case report – being the ﬁrst on combination therapy with
IFN and a JAK1-2 inhibitor – has convincingly shown that this
combinatorial approach is highly efﬁcacious in a PV-patient with
advanced disease and a large tumor burden, as evidenced by
pronounced splenomegaly and a high JAK2V617F-allele burden.
Most importantly, the treatment was associated with a rapid
decline in the JAK2V617F-allele burden within a few months,
which has been argued not to be possible due to inhibition of
IFN-signaling during JAK-inhibitor treatment. Of note, serial ultra-
sound examinations of the carotid arteries showed an improve-
ment of the blood-ﬂow. Whether this improvement was attributed
to normalization of the hematocrit, leukocyte and platelet-counts
or might be due to the anti-inﬂammatory potential of Rux within
the carotid artery wall diminishing inﬂammation (atherosclerosis
being a chronic inﬂammatory disease) is elusive but certainly
warrants further investigation.
The potent efﬁcacy of this combination therapy in our patient
may be explained by several mechanisms [1]. Firstly, using Rux
with a half-life of approximately 3 h may leave a time-window of a
several hours daily in which efﬁcient IFN-signaling is possible. Also
the possibility exists that – at a certain level of JAK-inhibition by
Rux – the IFN-signaling is merely modulated rather than totally
abolished. Secondly, the potent anti-inﬂammatory effect of JAK1-2
inhibition may have reduced or eliminated the (transient) sys-
temic inﬂammation response, mediated by the release of inﬂam-
matory cytokines in the context of the IFN- mediated tumor
killing. Thirdly, by reducing the release of TNF-alpha – a cytokine,
which has been shown to facilitate clonal evolution – concomitant
JAK1-2 inhibition with Rux might have improved the tumor-
reducing effect of IFN. Fourthly, the possibility exists that IFN
might actually have augmented the effects of JAK1-2 inhibition, as
IFN blocks the intramedullary release of cytokines from bone
marrow stroma. These cytokines have been shown to protect
JAK2V617F-positive tumor cells from the JAK1-2 inhibitor-induced
tumor killing [2]. Fifthly, most recently, chronic inﬂammation with
oxidative stress and generation of reactive oxygen species (ROS)
has been argued to be of major importance for clonal evolution
and disease progression in MPNs [1–3]. Indeed, MPNs have been
shown most recently to be associated with pronounced oxidative
stress and ROS accumulation and most lately the JAK2V617F
mutation per se has been demonstrated to generate ROS [4]. Since
IFN-signaling is impaired by oxidative stress it is most intriguing
to consider, if a combinatorial approach with a JAK1-2 inhibitor
indeed might improve IFN-signaling – otherwise potentially
impaired by oxidative stress mediated by the MPN-clone itself
[2,4].
Accordingly, considering all the above anti-inﬂammatory
actions, a combinatorial approach with IFN and a JAK1-2 inhibitor
may prove to be more efﬁcacious than single-agent therapy [5].
Furthermore, IFN-a2 also activates dormant stem cells [6] and
mobilizes them to be targets for potent JAK1-2 inhibition. Thus, by
concurrently depleting dormant JAK2V617F MPN propagating
stem cells with IFN-alpha [7] and targeting the proliferating
downstream progeny with JAK1-2 inhibitors [6,8], a combination
of IFN and a JAK1-2 inhibitor may be a highly efﬁcacious treatment
modality in MPNs with superior tumor control and less IFN side-
effects [1,2].
Our patient tolerated the combination therapy exceedingly well
without side effects or myelosuppression, which otherwise might
be a concern, taking into consideration that both JAK inhibition
and IFN may be associated with myelosuppression. However, in
the context of treating MPN patients with elevated cell counts (the
pancytopenic myeloﬁbrosis patient with severe myeloﬁbrosis is
not a candidate for IFN and accordingly neither for combination
therapy) myelosuppression is not likely to occur provided that
low-dose IFN (e.g., Pegasys 45 mg subcutaneously once weekly)
and low-dose Rux (e.g., ruxolitinib 10 mg twice daily) are being
used. Otherwise, combination therapy with IFNþRux is not
expected to be associated with any particular risk or side effects.
In fact, the ﬂue-like symptoms during the initial phase of IFN
treatment, being likely associated with “a systemic inﬂammation
response”, may actually vanish, when IFN-a2 is combined with a
potent anti-inﬂammatory agent such as Rux.
In conclusion, describing a single case observation of a PV-
patient we have for the ﬁrst time delivered the “proof of concept”
that combination therapy with Rux and “low-dose” IFN is safe,
tolerable and highly efﬁcacious in PV, as evidenced by a rapid
reduction in the JAK2V617F-allele burden in concert with normal-
ization of blood counts and resolution of pronounced splenome-
galy and constitutional symptoms. This observation warrants
prospective trials of this combinatorial approach in patients with
PV and hyperproliferative MF to assess, if combination therapy
induces a more rapid decline in the JAK2V617F-allele burden
compared to monotherapy with either drug. In addition, studies
are urgently needed to elucidate, if combination therapy – by
alleviating potential side effects of IFN, which otherwise might
Fig. 1. Hemoglobin, leukocyte and platelet levels during combination therapy with
Ruxolitinib and Peg-IFN-alpha2a.
Fig. 2. JAK2 V617F allele burden over time.
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disqualify for further IFN- treatment, might actually rescue IFN-
intolerant or IFN-non-responsive patients, thereby improving their
quality of life and likely maintaining the goal of achieving major
molecular remission and hopefully “minimal residual disease” as
well [1,2,9,10].
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